163 related articles for article (PubMed ID: 12668004)
1. Design, synthesis and biological activity of beta-carboline-based type-5 phosphodiesterase inhibitors.
Maw GN; Allerton CM; Gbekor E; Million WA
Bioorg Med Chem Lett; 2003 Apr; 13(8):1425-8. PubMed ID: 12668004
[TBL] [Abstract][Full Text] [Related]
2. New pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as potent and selective PDE5 inhibitors.
Feixas J; Giovannoni MP; Vergelli C; Gavaldà A; Cesari N; Graziano A; Dal Piaz V
Bioorg Med Chem Lett; 2005 May; 15(9):2381-4. PubMed ID: 15837329
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and phosphodiesterase 5 inhibitory activity of novel pyrido[1,2-e]purin-4(3H)-one derivatives.
Xia G; Li J; Peng A; Lai S; Zhang S; Shen J; Liu Z; Chen X; Ji R
Bioorg Med Chem Lett; 2005 Jun; 15(11):2790-4. PubMed ID: 15878277
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and SAR of tetracyclic pyrroloquinolones as phosphodiesterase 5 inhibitors.
Jiang W; Alford VC; Qiu Y; Bhattacharjee S; John TM; Haynes-Johnson D; Kraft PJ; Lundeen SG; Sui Z
Bioorg Med Chem; 2004 Mar; 12(6):1505-15. PubMed ID: 15018924
[TBL] [Abstract][Full Text] [Related]
5. The discovery of novel, potent and selective PDE5 inhibitors.
Bi Y; Stoy P; Adam L; He B; Krupinski J; Normandin D; Pongrac R; Seliger L; Watson A; Macor JE
Bioorg Med Chem Lett; 2001 Sep; 11(18):2461-4. PubMed ID: 11549447
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of xanthine analogues as potent and selective PDE5 inhibitors.
Wang Y; Chackalamannil S; Hu Z; Boyle CD; Lankin CM; Xia Y; Xu R; Asberom T; Pissarnitski D; Stamford AW; Greenlee WJ; Skell J; Kurowski S; Vemulapalli S; Palamanda J; Chintala M; Wu P; Myers J; Wang P
Bioorg Med Chem Lett; 2002 Nov; 12(21):3149-52. PubMed ID: 12372521
[TBL] [Abstract][Full Text] [Related]
7. The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 1: 5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione analogues.
Daugan A; Grondin P; Ruault C; Le Monnier de Gouville AC; Coste H; Kirilovsky J; Hyafil F; Labaudinière R
J Med Chem; 2003 Oct; 46(21):4525-32. PubMed ID: 14521414
[TBL] [Abstract][Full Text] [Related]
8. Optimization of substituted N-3-benzylimidazoquinazolinone sulfonamides as potent and selective PDE5 inhibitors.
Rotella DP; Sun Z; Zhu Y; Krupinski J; Pongrac R; Seliger L; Normandin D; Macor JE
J Med Chem; 2000 Dec; 43(26):5037-43. PubMed ID: 11150175
[TBL] [Abstract][Full Text] [Related]
9. The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione analogues.
Daugan A; Grondin P; Ruault C; Le Monnier de Gouville AC; Coste H; Linget JM; Kirilovsky J; Hyafil F; Labaudinière R
J Med Chem; 2003 Oct; 46(21):4533-42. PubMed ID: 14521415
[TBL] [Abstract][Full Text] [Related]
10. Exploring the PDE5 H-pocket by ensemble docking and structure-based design and synthesis of novel β-carboline derivatives.
Ahmed NS; Ali AH; El-Nashar SM; Gary BD; Fajardo AM; Tinsley HN; Piazza GA; Negri M; Abadi AH
Eur J Med Chem; 2012 Nov; 57():329-43. PubMed ID: 23117589
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and structure-activity relationship of functionalized tetrahydro-β-carboline derivatives as novel PDE5 inhibitors.
Ahmed NS; Gary BD; Tinsley HN; Piazza GA; Laufer S; Abadi AH
Arch Pharm (Weinheim); 2011 Mar; 344(3):149-57. PubMed ID: 21384413
[TBL] [Abstract][Full Text] [Related]
12. A solid-phase approach towards the synthesis of PDE5 inhibitors.
Beer D; Bhalay G; Dunstan A; Glen A; Haberthuer S; Moser H
Bioorg Med Chem Lett; 2002 Aug; 12(15):1973-6. PubMed ID: 12113821
[TBL] [Abstract][Full Text] [Related]
13. Tadalafil and vardenafil.
Neumeyer K; Kirkpatrick P
Nat Rev Drug Discov; 2004 Apr; 3(4):295-6. PubMed ID: 15124623
[No Abstract] [Full Text] [Related]
14. Structure-activity relationships of N-acyl pyrroloquinolone PDE-5 inhibitors.
Lanter JC; Sui Z; Macielag MJ; Fiordeliso JJ; Jiang W; Qiu Y; Bhattacharjee S; Kraft P; John TM; Haynes-Johnson D; Craig E; Clancy J
J Med Chem; 2004 Jan; 47(3):656-62. PubMed ID: 14736245
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors.
Burnouf C; Auclair E; Avenel N; Bertin B; Bigot C; Calvet A; Chan K; Durand C; Fasquelle V; Féru F; Gilbertsen R; Jacobelli H; Kebsi A; Lallier E; Maignel J; Martin B; Milano S; Ouagued M; Pascal Y; Pruniaux MP; Puaud J; Rocher MN; Terrasse C; Wrigglesworth R; Doherty AM
J Med Chem; 2000 Dec; 43(25):4850-67. PubMed ID: 11123995
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and evaluation of polycyclic pyrazolo[3,4-d]pyrimidines as PDE1 and PDE5 cGMP phosphodiesterase inhibitors.
Xia Y; Chackalamannil S; Czarniecki M; Tsai H; Vaccaro H; Cleven R; Cook J; Fawzi A; Watkins R; Zhang H
J Med Chem; 1997 Dec; 40(26):4372-7. PubMed ID: 9435906
[TBL] [Abstract][Full Text] [Related]
17. Novel, potent, and selective phosphodiesterase 5 inhibitors: synthesis and biological activities of a series of 4-aryl-1-isoquinolinone derivatives.
Ukita T; Nakamura Y; Kubo A; Yamamoto Y; Moritani Y; Saruta K; Higashijima T; Kotera J; Takagi M; Kikkawa K; Omori K
J Med Chem; 2001 Jun; 44(13):2204-18. PubMed ID: 11405657
[TBL] [Abstract][Full Text] [Related]
18. High biochemical selectivity of tadalafil, sildenafil and vardenafil for human phosphodiesterase 5A1 (PDE5) over PDE11A4 suggests the absence of PDE11A4 cross-reaction in patients.
Weeks JL; Zoraghi R; Beasley A; Sekhar KR; Francis SH; Corbin JD
Int J Impot Res; 2005; 17(1):5-9. PubMed ID: 15538396
[TBL] [Abstract][Full Text] [Related]
19. Design of novel β-carboline derivatives with pendant 5-bromothienyl and their evaluation as phosphodiesterase-5 inhibitors.
El-Gamil DS; Ahmed NS; Gary BD; Piazza GA; Engel M; Hartmann RW; Abadi AH
Arch Pharm (Weinheim); 2013 Jan; 346(1):23-33. PubMed ID: 23307609
[TBL] [Abstract][Full Text] [Related]
20. Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED.
Boyle CD; Xu R; Asberom T; Chackalamannil S; Clader JW; Greenlee WJ; Guzik H; Hu Y; Hu Z; Lankin CM; Pissarnitski DA; Stamford AW; Wang Y; Skell J; Kurowski S; Vemulapalli S; Palamanda J; Chintala M; Wu P; Myers J; Wang P
Bioorg Med Chem Lett; 2005 May; 15(9):2365-9. PubMed ID: 15837326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
